AR059329A1 - Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion - Google Patents
Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacionInfo
- Publication number
- AR059329A1 AR059329A1 ARP070100479A ARP070100479A AR059329A1 AR 059329 A1 AR059329 A1 AR 059329A1 AR P070100479 A ARP070100479 A AR P070100479A AR P070100479 A ARP070100479 A AR P070100479A AR 059329 A1 AR059329 A1 AR 059329A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- alkoxy
- hydrogen
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 13
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- -1 halogen-C1-8 alkyl Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Reivindindicacion 1: Un compuesto de la formula (1) en la que -X-Y- es -CRa=CRc- o -CRa=N- o -CRaRb-CRcRd-, en los que Ra, Rb, Rc y Rd se eligen con independencia entre sí entre el grupo formado por hidrogeno y alquilo C1-8; R1, R2, R34 y R5 se eligen con independencia entre sí entre el grupo formado por hidrogeno, alquilo C1-8, alcoxi C1-8, halogeno y halogeno-alquilo C1-8; R3 es Si (alquilo C1-6)3; R6 se elige entre el grupo formado por hidrogeno y alquilo C1-8; R7 se elige entre el grupo formado por hidrogeno, alquilo C1-8, hidroxi y halogeno; R8 se elige entre el grupo formado por alquilo C1-8, alquenilo C2-8, halogeno-alquilo C1-8, heterociclilo, heteroarilo, que está sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre alquilo C1-8, alcoxi C1-8, halogeno-alquilo C1-8, halogeno-alcoxi C1-8 y halogeno, fenilo, que está sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre alquilo C1-8, alcoxi C1-8, halogeno-alquilo C1-8, halogeno-alcoxi C1-8 y halogeno, -OR12, en el que R12 es alquilo C1-8 o fenilo, que está sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre alquilo C1-8, alcoxi C1-8, halogeno-alquilo C1-8, halogeno-alcoxi C1-8 y halogeno, -NR13R14, en el que R13 y R14 con independencia entre sí se eligen entre hidrogeno, alquilo C1-8, y fenilo, que está sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre alquilo C1-8, alcoxi C1-8, halogeno- alquilo C1-8, halogeno-alcoxi C1-8 y halogeno, y -C(O)-OR15, en el que R15 es hidrogeno o alquilo C1-8; R9, R10 y R11 con independencia entre sí se eligen entre el grupo formado por hidrogeno, alquilo C1-8, cicloalquilo, alcoxi C1-8, halogeno- alquilo C1-8 y halogeno; n es el numero 1, 2 o 3; y todas sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06101377 | 2006-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059329A1 true AR059329A1 (es) | 2008-03-26 |
Family
ID=38055241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100479A AR059329A1 (es) | 2006-02-07 | 2007-02-06 | Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7572823B2 (es) |
| EP (1) | EP1984002B1 (es) |
| JP (1) | JP4927098B2 (es) |
| KR (1) | KR101152718B1 (es) |
| CN (1) | CN101378763B (es) |
| AR (1) | AR059329A1 (es) |
| AT (1) | ATE492283T1 (es) |
| BR (1) | BRPI0707701A2 (es) |
| CA (1) | CA2640662C (es) |
| DE (1) | DE602007011398D1 (es) |
| ES (1) | ES2355600T3 (es) |
| IL (1) | IL192955A0 (es) |
| TW (1) | TW200738627A (es) |
| WO (1) | WO2007090750A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678818B2 (en) * | 2006-02-07 | 2010-03-16 | Hoffmann-La Roche Inc. | Anthranilamide and 2-amino-heteroarene-carboxamide compounds |
| US7745477B2 (en) * | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| EP2049493B1 (en) * | 2006-07-31 | 2012-03-21 | Cadila Healthcare Limited | Compounds suitable as modulators of hdl |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2345103C (en) * | 1998-09-25 | 2011-04-26 | Monsanto Company | (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| US6780883B2 (en) * | 1998-11-05 | 2004-08-24 | Warner-Lambert Company | Amide inhibitors of microsomal triglyceride transfer protein |
| CN1289467C (zh) | 2002-08-30 | 2006-12-13 | 日本烟草产业株式会社 | 二苄胺化合物及其药物用途 |
| JP3630676B2 (ja) * | 2002-08-30 | 2005-03-16 | 日本たばこ産業株式会社 | ジベンジルアミン化合物及びその医薬用途 |
| JP4787254B2 (ja) | 2004-08-05 | 2011-10-05 | エフ．ホフマン−ラ ロシュ アーゲー | インドール、インダゾールまたはインドリン誘導体 |
| CA2625988A1 (en) * | 2005-10-19 | 2007-04-26 | Merck & Co., Inc. | Cetp inhibitors |
-
2007
- 2007-01-26 US US11/698,677 patent/US7572823B2/en not_active Expired - Fee Related
- 2007-01-29 BR BRPI0707701-7A patent/BRPI0707701A2/pt not_active IP Right Cessation
- 2007-01-29 JP JP2008553712A patent/JP4927098B2/ja not_active Expired - Fee Related
- 2007-01-29 CN CN2007800044440A patent/CN101378763B/zh not_active Expired - Fee Related
- 2007-01-29 AT AT07712128T patent/ATE492283T1/de active
- 2007-01-29 KR KR1020087019283A patent/KR101152718B1/ko not_active Expired - Fee Related
- 2007-01-29 EP EP07712128A patent/EP1984002B1/en not_active Not-in-force
- 2007-01-29 DE DE602007011398T patent/DE602007011398D1/de active Active
- 2007-01-29 CA CA2640662A patent/CA2640662C/en not_active Expired - Fee Related
- 2007-01-29 ES ES07712128T patent/ES2355600T3/es active Active
- 2007-01-29 WO PCT/EP2007/050813 patent/WO2007090750A1/en not_active Ceased
- 2007-02-05 TW TW096104080A patent/TW200738627A/zh unknown
- 2007-02-06 AR ARP070100479A patent/AR059329A1/es not_active Application Discontinuation
-
2008
- 2008-07-22 IL IL192955A patent/IL192955A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4927098B2 (ja) | 2012-05-09 |
| AU2007213833A1 (en) | 2007-08-16 |
| US20070185182A1 (en) | 2007-08-09 |
| EP1984002A1 (en) | 2008-10-29 |
| BRPI0707701A2 (pt) | 2011-05-10 |
| WO2007090750A1 (en) | 2007-08-16 |
| DE602007011398D1 (de) | 2011-02-03 |
| JP2009526006A (ja) | 2009-07-16 |
| KR20080094907A (ko) | 2008-10-27 |
| ATE492283T1 (de) | 2011-01-15 |
| US7572823B2 (en) | 2009-08-11 |
| IL192955A0 (en) | 2009-02-11 |
| CA2640662C (en) | 2014-04-22 |
| CA2640662A1 (en) | 2007-08-16 |
| TW200738627A (en) | 2007-10-16 |
| CN101378763A (zh) | 2009-03-04 |
| KR101152718B1 (ko) | 2012-06-18 |
| ES2355600T3 (es) | 2011-03-29 |
| CN101378763B (zh) | 2013-05-22 |
| EP1984002B1 (en) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059329A1 (es) | Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR050620A1 (es) | Derivados de n-2 adamantanil -2- fenoxi- acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR062110A1 (es) | Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico | |
| AR076067A1 (es) | Composiciones y metodos para modular la senda de senalizacion de wnt | |
| AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| CO6160235A2 (es) | Isoxazolinas insecticidas | |
| AR056307A1 (es) | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| ES2294313T3 (es) | Derivados de piridina como moduladores del receptor cb2. | |
| AR066531A1 (es) | Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| CL2020002253A1 (es) | Derivados de 2,4 - diaminoquinazolina y usos médicos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |